Taxane-induced peripheral neuropathy more common in patients with diabetes longer than 5 years
the ONA take:
Patients receiving taxane-based therapy who have had diabetes for more than 5 years may be at a higher risk for developing severe peripheral sensory neuropathy, according to a new study published online ahead of print in the journal Supportive Care in Cancer.
For the study, researchers in Turkey sought to determine whether the presence of diabetes mellitus impacts the incidence and severity of peripheral sensory neuropathy in patients undergoing taxane therapy for cancer. Researchers retrospectively analyzed data from 374 patients receiving taxane therapy at a single institution. Of those, 21.6% had diabetes.
Results showed that the incidence of grade 1 peripheral neuropathy in patients receiving taxane-based therapy was 33.4% in non-diabetics and 25.9% in those with diabetes; however, the incidence of grade 2 or higher peripheral neuropathy was 15% and 34.6%, respectively.
Researchers found that the overall incidence of peripheral neuropathy was 48.8% in non-diabetic patients, 52.8% in patients with diabetes less than 5 years, and 75% in patients with diabetes for longer than 5 years.
Patients receiving taxane-based therapy who have had diabetes for more than 5 years may be at a higher risk for neuropathy.
- Prehabilitation Program Improves Preoperative Fitness in Patients With Colorectal Cancer
- Acupuncture Improves Postoperative Symptoms in Women Undergoing Surgery for Breast Cancer
- Combination of Gemcitabine and New CHK1 Inhibitor Is Effective in Soft Tissue Sarcomas
- Alcohol Consumption, Particularly White Wine, Associated With Increased Risk of Melanoma
- In HER2+ Breast Cancer, Higher TIL Levels Associated With Improved OS
- Exercise is as Effective in Treating Metastatic Prostate Cancer as Medication
- Walnut Consumption Changes Gut Microbiome, Decreases Growth of Colon Cancer in Mice
- Vaccine Enters Phase I Study for Safety and Effectiveness in Multiple Myeloma
- Timing Chemotherapy Administration to Circadian Rhythm Improves Drug Effectiveness
- New Therapy Blocks Breast Cancer Cells From Entering and Hiding in Bone Marrow to Form Latent Metastases
- Costs, Complications Higher for Women Who Undergo Second Surgery After BCS
- Omitting RT in Certain Older Women With Early Breast Cancer is Safe
- Fluorescent Nanoparticles Represent Novel Detection Method of HER2 Expression
- Assessment of Stromal Features in DCIS Requires Robustness
- Profile of Tivantinib and its Potential in the Treatment of Hepatocellular Carcinoma: the evidence to date
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|